"Effect of valerenic acid on neuroinflammation in a MPTP-induced mouse model of Parkinson's disease". (June 2020)

• Record Type: Journal Article
• Authors: Rodríguez-Cruz, Alfredo; Romo-Mancillas, Antonio; Mendiola-Precoma, Jesus; Escobar-Cabrera, Jesica Esther; García-Alcocer, Guadalupe; Berumen, Laura Cristina
• Is Part Of: IBRO reports. Volume 8(2020)
• Page Start: 28
• Page End: 35
• Publication Date: 2020-06
• Subjects: PD Parkinson´s disease -- TH tyrosine hydroxylase -- V.A. valerenic acid -- MPTP 1-methyl-4-phenyl-12, 3, 6-tetrahidropyridine -- PBS phosphate buffered solution -- GFAP glial fibrillary acid protein -- LSD lysergic acid diethylamide; Parkinson´s disease -- MPTP -- Valerenic acid -- C57BL/6J mice -- CD-1 mice -- Molecular docking -- 5-HT5A; Nervous system -- Periodicals; Brain -- Periodicals; Brain -- Research -- Periodicals; Nervous system; Brain -- Research; Brain; Neurology; Nervous System Physiological Phenomena; Electronic journals; Periodicals; Fulltext; Internet Resources; Periodicals; Periodical
• DOI: 10.1016/j.ibror.2019.12.002
• Languages: English
• ISSNs: 2451-8301

Abstract

Highlights: Valerenic acid modulates the neuropathological markers of Parkinson´s disease. Valerenic acid attenuates neuroinflammation in a Parkinson´s disease model. Astrocytes and cytokines are targets in the anti-inflammatory effect of valerenic acid. The molecular docking confirms the interaction of valerenic acid with 5-HT5A receptors. Abstract: Parkinson´s disease is the most important neuromotor pathology due to the prominent loss of dopaminergic neurons in the substantia nigra pars compacta . There is an inherent deficiency of dopamine in Parkinson´s disease, which is aggravated when neuroinflammatory processes are present. Several biomolecules are interesting candidates for the regulation of inflammation and possible neuroprotection, such as valerenic acid, one of the main components of Valeriana officinalis. A 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine hydrochloride (MPTP)-induced mouse model of Parkinson's disease was developed to evaluate the motor effects of valerenic acid. The evaluation was carried out with four tests (an invert screen test for muscle strength, cross beam test, open field mobility test and lifting on hind legs test). Subsequently, the neuroinflammatory process was evaluated through ELISA of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α and IFN-γ). The decreases in the inflammatory and neurodegenerative processes were evaluated by Western blot and immunohistochemistry analyses of the tissues, which included an evaluation of the tyrosine hydroxylase and GFAP proteins. Finally, the predicted mechanism of action of valerenic acid was supported by molecular docking calculations with the 5-HT5A receptor. The results indicate that the use of valerenic acid as a co-treatment decreases the neuroinflammation in Parkinson's disease induced by MPTP and provides evidence of a decrease in the evaluated pro-inflammatory cytokines and in the amount of GFAP in the mesencephalic area. Valerenic acid prevents neuroinflammation in a Parkinson's disease mouse model, which might reflect the neuroprotection of dopaminergic neurons with the recovery of motor ability.